These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21352268)

  • 1. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?
    Ma TK; Lam YY; Tan VP; Yan BP
    Br J Clin Pharmacol; 2011 Oct; 72(4):697-706. PubMed ID: 21352268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
    Furuta T; Iwaki T; Umemura K
    Br J Clin Pharmacol; 2010 Sep; 70(3):383-92. PubMed ID: 20716239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles.
    Liu Q; Dang DS; Chen YF; Yan M; Shi GB; Zhao QC
    Genet Test Mol Biomarkers; 2012 Nov; 16(11):1293-7. PubMed ID: 23046071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
    Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
    JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.
    Ellis KJ; Stouffer GA; McLeod HL; Lee CR
    Pharmacogenomics; 2009 Nov; 10(11):1799-817. PubMed ID: 19891556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature.
    Fefer P; Matetzky S
    Thromb Haemost; 2011 Aug; 106(2):203-10. PubMed ID: 21792462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the pharmacogenetics of clopidogrel.
    Cuisset T; Morange PE; Alessi MC
    Hum Genet; 2012 May; 131(5):653-64. PubMed ID: 22207144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
    J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.
    Hulot JS; Bura A; Villard E; Azizi M; Remones V; Goyenvalle C; Aiach M; Lechat P; Gaussem P
    Blood; 2006 Oct; 108(7):2244-7. PubMed ID: 16772608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitor and clopidogrel interaction: fact or fiction?
    Laine L; Hennekens C
    Am J Gastroenterol; 2010 Jan; 105(1):34-41. PubMed ID: 19904241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.
    Angiolillo DJ; Gibson CM; Cheng S; Ollier C; Nicolas O; Bergougnan L; Perrin L; LaCreta FP; Hurbin F; Dubar M
    Clin Pharmacol Ther; 2011 Jan; 89(1):65-74. PubMed ID: 20844485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacogenetics of clopidogrel and its clinical significance].
    Panchenko EP; Komarov AL
    Kardiologiia; 2012; 52(9):44-52. PubMed ID: 23098546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An insight into the interaction between clopidogrel and proton pump inhibitors.
    Shah BS; Parmar SA; Mahajan S; Mehta AA
    Curr Drug Metab; 2012 Feb; 13(2):225-35. PubMed ID: 22300021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Genetic variability in the efficacy of clopidogrel].
    Kristensen KE; Rasmussen HB; Hansen PR
    Ugeskr Laeger; 2013 Mar; 175(11):729-32. PubMed ID: 23480885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition.
    Zhang H; Ragueneau-Majlessi I; Levy RH
    Drug Metab Lett; 2009 Dec; 3(4):287-9. PubMed ID: 19995331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interaction between clopidogrel and proton pump inhibitors].
    Harmsze AM; de Boer A; Boot H; Deneer VH; Heringa M; Mol PG; Schalekamp T; Verduijn MM; Verheugt FW; le Comte M
    Ned Tijdschr Geneeskd; 2011; 155(28):A2442. PubMed ID: 21771377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel.
    Ma TK; Lam YY; Tan VP; Kiernan TJ; Yan BP
    Pharmacol Ther; 2010 Feb; 125(2):249-59. PubMed ID: 19919843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interaction between clopidogrel and proton pump inhibitors.
    Khalique SC; Cheng-Lai A
    Cardiol Rev; 2009; 17(4):198-200. PubMed ID: 19525682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
    Kelly RP; Close SL; Farid NA; Winters KJ; Shen L; Natanegara F; Jakubowski JA; Ho M; Walker JR; Small DS
    Br J Clin Pharmacol; 2012 Jan; 73(1):93-105. PubMed ID: 21689142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton pump inhibitors and clopidogrel.
    Gaglia MA; Waksman R
    Cardiovasc Ther; 2010 Jun; 28(3):169-76. PubMed ID: 20345494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.